HC Wainwright & Co. Reiterates Buy on Arbutus Biopharma, Maintains $6 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Arbutus Biopharma (NASDAQ:ABUS), maintaining a price target of $6.
July 11, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arbutus Biopharma's stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $6 price target.
Analyst ratings often influence the short-term price movement of stocks. A 'Buy' rating indicates that the analyst believes the stock will perform well in the future. The maintained price target of $6 also suggests that the analyst sees potential for the stock's price to increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100